US 5723299A
· Bell et al.
· 1998
[cited by applicant]
US 8278066B2
· Kundra
· 2012
[cited by applicant]
US 9791023B2
· Hwang et al.
· 2017
[cited by applicant]
EP 1118336
· 2001
[cited by applicant]
WO WO2006099019
· 2006
[cited by applicant]
WO WO2008085564
· 2008
[cited by applicant]
Barnett (2003) “Somatostatin and Somatostatin Receptor Physiology”, Endocrine, 20(3): 255-64.
[cited by examiner]
“Immune Cells,” National Institutes of Health, http://www.niaid.nih.gov/topics/immunesystem/immunecells/pages/default.aspx, downloaded Nov. 13, 2014.
[cited by applicant]
“Phagocytes,” National Institutes of Health, http://www.niaid.nih.gov/topics/immuneSystem/immuneCells/Pages/phagocytes.aspx, downloaded Nov. 13, 2014.
[cited by applicant]
“Somatic Cell,” Wikipedia, http://en.wikipedia.org/wiki/Somatic_cell, downloaded Nov. 13, 2014.
[cited by applicant]
Akinlolu et al., “Antiproliferative effects of
[cited by applicant]
Andreesen et al., “Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives,”
[cited by applicant]
Brower, “Search and Destroy: Recent Research Exploits Adult Stem Cell's Attraction to Cancer,”
[cited by applicant]
Dwyer et al., “Advances in mesenchymal stem cell-mediated gene therapy for cancer,”
[cited by applicant]
Extended European Search Report issued in European Application No. 11824117.3, mailed Apr. 13, 2015.
[cited by applicant]
Gajewski et al., “Innate and adaptive immune cells in the tumor microenvironment,”
[cited by applicant]
Gambhir et al., “Assays for noninvasive imaging of reporter gene expression”,
[cited by applicant]
Han et al., “Signalling Can be Uncoupled from Imaging of the Somatostatin Receptor Type 2,”
[cited by applicant]
Harrower et al., “The emerging technologies of neutral xenografting and stem cell transplantation for treating neurodegenerative disorders,”
[cited by applicant]
Hung et al., “Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging”,
[cited by applicant]
Krüger et al., “Immune based therapies in cancer,”
[cited by applicant]
Lopez et al., “Neuronal nitric oxide synthase is a SHP-1 substrate involved in sst2 somatostatin receptor growth inhibitory signaling”,
[cited by applicant]
Matthews et al., “Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer”, Clin Canc…
[cited by applicant]
Mearadji et al., “Somatostatin receptor gene therapy comined with targeted therapy with radiolabeled octreotide”,
[cited by applicant]
Office Action issued in Brazilian Application No. BR112013005711-4, mailed on Dec. 22, 2020.
[cited by applicant]
Office Action issued in Canadian Application No. 2,810,838, mailed on Jun. 23, 2017.
[cited by applicant]
Office Action issued in Canadian Application No. 2,810,838, mailed on Mar. 29, 2018.
[cited by applicant]
Office Action issued in Canadian Application No. 2,810,838, mailed on Mar. 11, 2019.
[cited by applicant]
Office Action issued in Canadian Application No. 2,810,838, mailed on Mar. 17, 2020.
[cited by applicant]
Office Action issued in European Application No. 11824117.3, mailed on Sep. 26, 2017.
[cited by applicant]
Office Action issued in European Application No. 11824117.3, mailed on Sep. 4, 2020.
[cited by applicant]
Office Action issued in European Application No. 11824117.3, mailed on Jan. 31, 2020.
[cited by applicant]
Office Action issued in European Application No. 11824117.3, mailed on Mar. 13, 2019.
[cited by applicant]
Office Action issued in European Application No. 11824117.3, mailed on Aug. 21, 2018.
[cited by applicant]
Office Action issued in Indian Application No. 2330/DELNP/2013, mailed on Jun. 13, 2018.
[cited by applicant]
Office Action issued in U.S. Appl. No. 13/821,541, mailed Apr. 17, 2014.
[cited by applicant]
Office Action issued in U.S. Appl. No. 13/821,541, mailed Dec. 9, 2014.
[cited by applicant]
Office Action issued in U.S. Appl. No. 13/821,541, mailed Jun. 30, 2014.
[cited by applicant]
Office Action issued in U.S. Appl. No. 13/821,541, mailed Nov. 26, 2014.
[cited by applicant]
Office Action issued in U.S. Appl. No. 15/647,840, mailed Mar. 29, 2019.
[cited by applicant]
Office Action issued in U.S. Appl. No. 15/647,840, mailed Nov. 2, 2018.
[cited by applicant]
Office Action issued in U.S. Appl. No. 16/659,986, mailed Apr. 28, 2022.
[cited by applicant]
PCT International Preliminary Report on Patentability issued in International Application No. PCT/US2011/050803, mailed Feb. 1, 2013.
[cited by applicant]
PCT International Search Report and Written Opinion issued in International Application No. PCT/US2011/050803, mailed Apr. 27, 2012.
[cited by applicant]
Rogers et al., “In vivo localization of [111In]-DTPA-d-Phe-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector”,
[cited by applicant]
Schmid and Varner, “Myeloid cell trafficking and tumor angiogenesis,”
[cited by applicant]
Schwartkop et al., “Agonist-independent internalization and activity of a c-terminally truncated somatostatin receptor subtype 2 (A349)”,
[cited by applicant]
Sutlu and Alici et al., “Natural killer cell-based immunotherapy in cancer: current insights and future prospects,”
[cited by applicant]
Wei et al., “Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression,”
[cited by applicant]
Wels et al., “Migratory neighbors and distant invaders: tumor-associated niche cells,”
[cited by applicant]